Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Inventory (2018 - 2025)

Historic Change in Inventory for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$5.6 million.

  • 10x Genomics' Change in Inventory rose 4196.9% to -$5.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$28.0 million, marking a year-over-year decrease of 38590.57%. This contributed to the annual value of -$28.0 million for FY2025, which is 38590.57% down from last year.
  • As of Q4 2025, 10x Genomics' Change in Inventory stood at -$5.6 million, which was up 4196.9% from -$7.3 million recorded in Q3 2025.
  • 10x Genomics' 5-year Change in Inventory high stood at $9.9 million for Q1 2024, and its period low was -$9.6 million during Q4 2024.
  • Moreover, its 5-year median value for Change in Inventory was $2.8 million (2022), whereas its average is $1.3 million.
  • As far as peak fluctuations go, 10x Genomics' Change in Inventory tumbled by 63207.55% in 2023, and later surged by 211314.03% in 2024.
  • 10x Genomics' Change in Inventory (Quarter) stood at $8.8 million in 2021, then plummeted by 83.71% to $1.4 million in 2022, then tumbled by 632.08% to -$7.6 million in 2023, then dropped by 26.33% to -$9.6 million in 2024, then skyrocketed by 41.97% to -$5.6 million in 2025.
  • Its Change in Inventory was -$5.6 million in Q4 2025, compared to -$7.3 million in Q3 2025 and -$7.0 million in Q2 2025.